Westfield Capital Management Co. LP lowered its position in Nektar Therapeutics (NASDAQ:NKTR) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,773,983 shares of the biopharmaceutical company’s stock after selling 256,556 shares during the quarter. Westfield Capital Management Co. LP owned about 2.43% of Nektar Therapeutics worth $73,781,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in NKTR. BlackRock Inc. increased its holdings in Nektar Therapeutics by 180,432.9% in the 1st quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock worth $470,234,000 after acquiring an additional 20,024,448 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in Nektar Therapeutics in the 1st quarter worth about $23,580,000. Marshall Wace North America L.P. purchased a new stake in Nektar Therapeutics in the 1st quarter worth about $23,580,000. Vanguard Group Inc. increased its holdings in Nektar Therapeutics by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 13,607,980 shares of the biopharmaceutical company’s stock worth $319,379,000 after acquiring an additional 634,700 shares during the last quarter. Finally, FMR LLC increased its holdings in Nektar Therapeutics by 42.4% in the 1st quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock worth $45,711,000 after acquiring an additional 580,341 shares during the last quarter. 95.15% of the stock is owned by institutional investors.
In other Nektar Therapeutics news, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $21.54, for a total value of $1,794,992.82. Following the completion of the sale, the chief executive officer now owns 235,837 shares in the company, valued at $5,079,928.98. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Howard W. Robin sold 91,714 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $19.26, for a total value of $1,766,411.64. Following the completion of the sale, the chief executive officer now owns 152,504 shares of the company’s stock, valued at approximately $2,937,227.04. The disclosure for this sale can be found here. In the last 90 days, insiders sold 320,962 shares of company stock valued at $6,615,210. Company insiders own 6.10% of the company’s stock.
Shares of Nektar Therapeutics (NKTR) traded up 0.23% on Friday, reaching $22.05. The company’s stock had a trading volume of 2,158,542 shares. The company’s market capitalization is $3.45 billion. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88. The company’s 50-day moving average is $20.16 and its 200 day moving average is $19.57.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The company had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.36) EPS. Equities analysts anticipate that Nektar Therapeutics will post ($0.94) earnings per share for the current fiscal year.
NKTR has been the subject of several recent research reports. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, July 21st. Roth Capital set a $33.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. HC Wainwright initiated coverage on Nektar Therapeutics in a report on Monday, August 7th. They issued a “buy” rating and a $31.00 price objective for the company. Finally, BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and a consensus target price of $26.10.
Nektar Therapeutics Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.